HOME >> BIOLOGY >> NEWS
Treatable psychiatric symptoms common with degenerative brain disease

Potentially treatable psychiatric problems are common in patients with degenerative brain diseases affecting movement and coordination, according to a study by Johns Hopkins scientists. Up to 80 per cent of those with either Huntington's disease or degenerative diseases affecting the cerebellum also suffer from depression, impaired thinking and changes in personality, the study found.

"Traditionally, there has been this distinction between neurological and psychiatric disorders, but it is an artificial distinction," said lead author Russell L. Margolis, M.D., associate professor of psychiatry at Hopkins and director of the Laboratory of Genetic Neurobiology.

"Indeed, the high rate of psychiatric disorders in these patients suggests that many, if not most, can benefit from treatment, even if the course of the brain disease itself cannot be reversed. Many symptoms can be eased, and the quality of life for these patients and their families can be greatly enhanced," says Margolis.

"Our findings of high rates of psychiatric disorders in Huntington's disease confirm the results of previous studies, and we believe we've found the first well-established link between serious psychiatric disorders and the cerebellum, a region at the back of the brain densely packed with nerve cells," notes Margolis.

In the study, Margolis and his colleagues conducted detailed interviews and analyzed brain images of three groups: 31 patients with degenerative cerebellar disease, 21 patients with Huntington's disease and 29 people who had no signs of brain disease. The results, reported in the August issue of the American Journal of Psychiatry, found that 77 per cent of patients with cerebellar disease had psychiatric disorders, and 81 per cent of Huntington's disease patients did so, rates nearly double those seen in healthy control subjects (41 per cent). Sixty-eight per cent of those with cerebellar disease suffered from mood disorders like depression, com
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
6-Aug-2002


Page: 1 2 3

Related biology news :

1. Brain serotonin enzyme finding might explain psychiatric disorders
2. Researchers caution against linking strep, neuropsychiatric disorders
3. New tool for studying animal models of neurological and psychiatric diseases
4. Environmental and genetic factors influence development of psychiatric disorder
5. Chronic respiratory symptoms prevalent among Alaska natives
6. Ritalin may improve Parkinsons symptoms, OHSU study says
7. UT Southwestern research halts narcolepsy symptoms
8. Dec. 17 JAMA study shows new biologic drug reduces psoriasis symptoms, improves quality of life
9. Imperial researchers show novel flu treatment eliminates symptoms in mice
10. Gene therapy delays death in mouse with symptoms of Lou Gehrigs disease
11. Spectrum of West Nile symptoms includes paralysis

Post Your Comments:
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... DUBLIN , May 20, 2015 Research ... announced the addition of the "2015 Global ... to their offering. The primary goal ... of flow cytometry instruments and reagents. Key information ... drive the selection of flow cytometers, predominantly used ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
Cached News: